Biohaven (NYSE:BHVN) Price Target Raised to $21.00

Biohaven (NYSE:BHVN) had its price target upped by Morgan Stanley from $19.00 to $21.00 in a report issued on Tuesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Other research analysts also recently issued reports about the company. Weiss Ratings upgraded Biohaven from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Canaccord Genuity Group increased their price target on Biohaven from $21.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Citigroup restated a “buy” rating on shares of Biohaven in a report on Friday, September 18th. TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a research report on Wednesday, August 26th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research report on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.80.

Biohaven Stock Performance

Shares of NYSE BHVN opened at $13.88 on Tuesday. The company has a 50-day simple moving average of $13.64 and a 200-day simple moving average of $12.30. The company has a debt-to-equity ratio of 21.23, a current ratio of 3.05 and a quick ratio of 3.05. The company has a market cap of $2.10 billion, a PE ratio of -3.60 and a beta of 1.36. Biohaven has a 12 month low of $7.48 and a 12 month high of $18.24.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, equities analysts anticipate that Biohaven will post -3.05 earnings per share for the current year.

Institutional Investors Weigh In On Biohaven

Several hedge funds have recently modified their holdings of the stock. Inspire Investing LLC grew its position in Biohaven by 2.4% during the third quarter. Inspire Investing LLC now owns 47,089 shares of the company’s stock valued at $629,000 after acquiring an additional 1,113 shares during the period. Integrated Wealth Concepts LLC increased its stake in Biohaven by 10.4% during the second quarter. Integrated Wealth Concepts LLC now owns 12,653 shares of the company’s stock worth $188,000 after acquiring an additional 1,189 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Biohaven by 43.3% in the 2nd quarter. IFP Advisors Inc now owns 6,011 shares of the company’s stock worth $89,000 after purchasing an additional 1,816 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its stake in shares of Biohaven by 12.9% in the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 17,500 shares of the company’s stock valued at $234,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Essential Partners LLC lifted its stake in shares of Biohaven by 31.7% in the 1st quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock valued at $76,000 after purchasing an additional 2,169 shares in the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Key Biohaven News

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Biohaven said its pivotal Phase 3 trial of BHV-1300 for Graves’ disease is underway and presented three posters at the 2026 American Thyroid Association meeting. The program addresses a disease with no newly approved therapy in more than 70 years, offering potential longer-term upside, though the update did not report trial results. Biohaven Graves’ disease trial and ATA posters
• Positive Sentiment: HC Wainwright raised several earnings forecasts, including its FY2027 estimate from a loss of $3.05 to a loss of $1.26 per share, and its Q4 2026 estimate from a loss of $0.78 to a loss of $0.35. The revisions suggest the analyst expects losses to narrow faster than previously projected. Biohaven analyst estimates
• Neutral Sentiment: A headline reports that a Morgan Stanley analyst expects BHVN shares to rise, but the provided information does not include the analyst’s reasoning or price target. Morgan Stanley analyst outlook
• Negative Sentiment: Despite improving forecasts, HC Wainwright maintained a “Neutral” rating and a $10 price target—below the stock’s recently reported trading level—which may weigh on sentiment. The trial announcement also provides no efficacy data yet, so clinical uncertainty remains.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.